Phenerine 50 mg Sugar-coated tablet

Parkinsonism.

One tablet twice a day to two tablets four times a day.

Prostatic enlargement, paralytic ileus, pyloric stenosis, closed-angle glaucoma and patients with a narrow angle between the iris and the cornea. Should be used with caution in conditions characterised by tachycardia, such as thyrotoxicosis, cardiac insufficiency or failure, and in cardiac surgery.

In the treatment of Parkinsonism, increases in dosage, and transfer to other forms of treatment should be gradual and anticholinergic medicines should not be withdrawn abruptly. If higher doses provoke severe mental disturbances, the medicine should be discontinued, but minor reactions may be controlled by reducing the dosage until tolerance has developed.

PHENERINE contains lactose monohydrate and sucrose which may have an effect on the glycaemic control of patients with diabetes mellitus. Patients with the rare hereditary conditions of galactose intolerance e.g. galactosaemia, Lapp lactase deficiency, glucose-galactose malabsorption, sucrase-isomaltase insufficiency or fructose intolerance should not take PHENERINE.

The effects of anticholinergic medicines may be enhanced by the concomitant administration of other medicines with anticholinergic properties, such as amantadine, some antihistaminics, butyrophenones and phenothiazines, and tricyclic anti-depressants.

Not known.

Not specified.

Dryness of the mouth with difficulty in swallowing, thirst, dilatation of the pupils with loss of accommodation and photophobia, increased intra-ocular pressure, flushing and dryness of the skin, bradycardia followed by tachycardia, with palpitations and arrhythmias, a desire to urinate with the inability to do so, as well as reduction in the tone and motility of the gastrointestinal tract leading to constipation. Occasionally vomiting, giddiness and staggering may occur. Retrosternal pain may occur due to increased gastric reflux.

Symptoms: Tachycardia, rapid or stertorous respiration, hyperpyrexia, restlessness, confusion and excitement, and hallucinations passing into delirium. Depression of the central nervous system, with hypertension or circulatory failure and respiratory depression.

Treatment: Treatment of acute poisoning is to empty the stomach. A saline purgative should be given to promote peristalsis. Excitement may be controlled by small doses of a short-acting barbiturate. Supportive therapy may require oxygen and assisted respiration, icebags or alcohol sponges for hyperpyrexia, especially in children, bladder catheterisation, and the administration of fluids.